{
  "abstract": "Prolonged SARS-CoV-2 PCR positivity is increasingly recognized in immunocompromised patients. We retrospectively analyzed four patients with B-cell lymphoma and prior anti-CD20 antibody therapy who exhibited prolonged PCR positivity after COVID-19 diagnosis. The median duration of PCR positivity was 57 days (range, 47-78 days); lymphoma treatment was interrupted in one patient and could not be resumed in another. Three patients received nirmatrelvir/ritonavir and became PCR negative 5-14 days after treatment initiation. These findings suggest that prolonged SARS-CoV-2 PCR positivity may disrupt lymphoma treatment and that PCR negativity was observed shortly after nirmatrelvir/ritonavir treatment in selected patients.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology Fukushima Medical University Fukushima Japan.",
    "Department of Hematology Fukushima Minami Hospital Fukushima Japan."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yutaka Natori",
      "orcid": "0000-0002-9535-5298"
    },
    {
      "affs": [
        1
      ],
      "name": "Hideyoshi Noji"
    },
    {
      "affs": [
        1
      ],
      "name": "Akiko Shichishima-Nakamura"
    },
    {
      "affs": [
        1
      ],
      "name": "Satoru Kikuchi"
    },
    {
      "affs": [
        0
      ],
      "name": "Shigehira Saji"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/etsc4sj2bt3tc.bib",
  "cited_by": 0,
  "doi": "10.1002/jha2.70442",
  "fulltext_url": "https://europepmc.org/articles/PMC13695328",
  "id": "etsc4sj2bt3tc",
  "issns": [
    "2688-6146"
  ],
  "landing_url": "https://europepmc.org/article/MED/42927348",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC633-647.5"
    ],
    [
      "openalex",
      "2725|COVID-19 Clinical Research Studies"
    ]
  ],
  "openalex": "W7223461470",
  "pdf_url": "https://europepmc.org/articles/PMC13695328?pdf=render",
  "pmcid": "PMC13695328",
  "pmid": "42927348",
  "published": "2026-10-24",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/etsc4sj2bt3tc.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42927348",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42927348"
    },
    {
      "first_seen": "2026-10-31T14:21:55Z",
      "native_id": "0817247d1558497cb394204628ecc0d2",
      "source": "doaj",
      "url": "https://doi.org/10.1002/jha2.70442"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2725|COVID-19 Clinical Research Studies",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Nirmatrelvir/Ritonavir and Subsequent PCR Negativity in Patients With B-Cell Lymphoma and Prolonged SARS-CoV-2 PCR Positivity: A Case Series.",
  "title_text": "Nirmatrelvir/Ritonavir and Subsequent PCR Negativity in Patients With B-Cell Lymphoma and Prolonged SARS-CoV-2 PCR Positivity: A Case Series.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T14:21:55Z",
  "url": "https://research.draconitic.com/paper/etsc4sj2bt3tc",
  "venue": "EJHaem",
  "versions": []
}